Approximately half of people with early-stage non-small cell lung cancer (NSCLC) experience their cancer coming back after surgery, despite also receiving chemotherapy. 1,2 Even with the efforts of the finest surgeon, some cancer cells can remain, with the risk that they can grow into new tumours later on.
This risk of recurrence has a profound impact on a person’s wellbeing and quality of life. “Living with the fear of cancer returning can be a huge psychosocial burden for people recovering from lung cancer surgery,” says Mark Brooke, CEO of the Lung Foundation of Australia.
Lung cancer is a complex form of cancer, made up of numerous different subtypes. The earlier lung cancer is diagnosed, the more effective treatments can be, meaning patients may live longer and have better treatment outcomes.3,4 Unfortunately, many people are diagnosed with advanced disease, after the tumour has spread.4
“We’re on a mission to put the possibility of living free from cancer within reach of as many people as possible,” says Charlie Fuchs, MD, MPH, Global Head of Oncology & Haematology Drug Development at Genentech and Roche. “Simply put, this starts with detecting and treating cancer early before it has spread. Early detection of NSCLC can change the treatment pathway for patients and increase the options available.”
With more and more personalised treatment approaches emerging in recent years, lung cancer treatment is becoming more targeted across all stages of disease, but despite this, we recognise there is still a long way to go.
Some patients may be given treatment before (neoadjuvant) or after (adjuvant) surgery. These treatments aim to prevent the cancer from coming back.
At Roche, we are committed to reshaping the way we diagnose, treat and care for people with this disease. As well as our work investigating treatment approaches in early-stage lung cancer, we are partnering with the community to address ongoing challenges for patients across their entire journey, from diagnosis, and treatment initiation, to ongoing monitoring and developing new forms of treatment administration to improve treatment experience.
References
Uramoto H and Tanaka F. Recurrence after surgery in patients with NSCLC. Translational lung cancer research, 2014;3(4):242-249.
Yano, T., Okamoto, T., Fukuyama, S. and Maehara, Y., 2014. Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer. World Journal of Clinical Oncology, 5(5), p.1048.
Cancer Research UK. Lung cancer risks becoming ‘forgotten disease’ of the coronavirus pandemic. Available from:
Blandin Knight, S., Crosbie, P.A., Balata, H., Chudziak, J., Hussell, T. and Dive, C., 2017. Progress and prospects of early detection in lung cancer. Open biology, 7(9), p.170070.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.